| Effectiveness of medical abortion with mifepristone and buccal misoprostol through 59 gestational days. | |
| | |
MedLine Citation:
|
PMID: 19698822 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: From 2001 to March 2006, Planned Parenthood Federation of America (Planned Parenthood) health centers throughout the United States provided medical abortions principally by a regimen of oral mifepristone, followed 24-48 h later by vaginal misoprostol. In late March 2006, analyses of serious uterine infections following medical abortions led Planned Parenthood to change the route of misoprostol administration and to employ additional measures to minimize subsequent serious uterine infections. In August 2006, we conducted an extensive audit of medical abortions with the new buccal misoprostol regimen so that patients could be given accurate information about the success rate of the new regimen. OBJECTIVES: We sought to evaluate the effectiveness of the buccal medical abortion regimen and to examine correlates of its success during routine service delivery. METHODS: In 2006, audits were conducted in 10 large urban service points to estimate the success rates of the buccal regimen. Success was defined as medical abortion without vacuum aspiration. These audits also permitted estimates of success rates with oral misoprostol following mifepristone in a subset in which 98% of the subjects stemmed from two sites. RESULTS: The effectiveness of the buccal misoprostol-mifepristone regimen was 98.3% for women with gestational ages below 60 days. The oral misoprostol-mifepristone regimen, used by 278 women with a gestational age below 50 days, had a success rate of 96.8%. CONCLUSION: In conjunction with 200 mg of mifepristone, use of 800 mcg of buccal misoprostol up to 59 days of gestation is as effective as the use of 800 mcg of vaginal misoprostol up to 63 days of gestation. |
| | |
Authors:
|
Mary Fjerstad; Irving Sivin; E Steve Lichtenberg; James Trussell; Kelly Cleland; Vanessa Cullins |
Publication Detail:
|
Type: Journal Article; Multicenter Study Date: 2009-05-02 |
Journal Detail:
|
Title: Contraception Volume: 80 ISSN: 1879-0518 ISO Abbreviation: Contraception Publication Date: 2009 Sep |
Date Detail:
|
Created Date: 2009-08-24 Completed Date: 2009-12-11 Revised Date: 2011-09-02 |
Medline Journal Info:
|
Nlm Unique ID: 0234361 Medline TA: Contraception Country: United States |
Other Details:
|
Languages: eng Pagination: 282-6 Citation Subset: IM |
Affiliation:
|
Planned Parenthood Federation of America, New York, NY 10001, USA. fjerstadm@ipas.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Abortifacient Agents, Nonsteroidal
/
administration & dosage* Abortifacient Agents, Steroidal / administration & dosage* Abortion, Induced / methods* Administration, Buccal Adult Female Gestational Age Humans Logistic Models Mifepristone / administration & dosage* Misoprostol / administration & dosage* Pregnancy Retrospective Studies Urban Population Young Adult |
| Grant Support | |
ID/Acronym/Agency:
|
R24 HD047879-05/HD/NICHD NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Abortifacient Agents, Nonsteroidal; 0/Abortifacient Agents, Steroidal; 59122-46-2/Misoprostol; 84371-65-3/Mifepristone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Physical and sexual violence and subsequent contraception use among reproductive aged women.
Next Document: Unexpected heaping in reported gestational age for women undergoing medical abortion.